$heff's $tation of $tocks & $olid DD

[usasingh1]

$LXRX Lexicon has a busy second half of the year with an expected FDA decision on its Telotristat etiprate, and top-line results from two Phase 3 clinical trials of sotagliflozin in patients with type 1 diabetes. Telotristat etiprate is the first investigational drug in clinical studies to target tryptophan hydroxylase, the rate-limiting enzyme involved in serotonin production. Earlier this year, the FDA accepted the company's NDA filing, granting priority review and establishing a Prescription Drug User Fee Act target action date of November 30. In addition, the European Medicines Agency recently accepted a marketing authorization application filed for telotristat etiprate by Ipsen (IPSEY). Separately, the company is developing Sotagliflozin as a potential treatment for type 1 and type 2 diabetes. Lexicon is conducting three Phase 3 clinical trials of sotagliflozin in patients with type 1 diabetes, two of which have completed enrollment and are expected to provide top-line results in the second half of 2016.